Atorvastatin Calcium Hydrate/Levamlodipine

阿托伐他汀钙/左旋氨氯地平

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAtorvastatin Calcium Hydrate/Levamlodipine
Drug Alias Name阿托伐他汀钙+马来酸左旋氨氯地平Atorvastatin Calcium+Levamlodipine Maleate马来酸左旋氨氯地平+阿托伐他汀钙马来酸左旋氨氯地平/阿托伐他汀钙
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsVoltage-gated L-type calcium channel blockers
TargetsVoltage-gated L-type calcium channelHMG-CoA reductase
Therapy Area/IndicationsHyperlipidemiasDyslipidemiasHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Levamlodipine MaleateAtorvastatin Calcium Hydrate
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdCspc Ouyi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCspc Ouyi Pharmaceutical Co LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesN/A
Active IndicationsDyslipidemiasHypertension
Inactive IndicationsHyperlipidemias

Other Information

ATC CodeN/A
Related LinksN/A